January 29, 2018
Investors who sued Pershing Square Capital Management LP and Valeant Pharmaceuticals over their alleged insider trading scheme ahead of Valeant's failed $55 billion effort to acquire Allergan Inc. filed papers Friday to begin the approval process for $290 million in settlements.
January 02, 2018
Hedge fund Pershing Square and Valeant Pharmaceuticals have reached a $290 million preliminary agreement to settle two investor suits in California federal court accusing them of an insider trading scheme in connection with Valeant's attempted $55 billion takeover of Allergan.
November 07, 2017
Investors behind two suits accusing Valeant Pharmaceuticals and hedge fund Pershing Square of an insider trading scheme in connection with Valeant's attempted $55 billion takeover of Allergan Inc. duked it out in California federal court Monday over proposals for how to handle potentially competing damages awards in their respective cases.
August 15, 2017
Investors behind a class action accusing Valeant Pharmaceuticals and hedge fund Pershing Square of an insider trading scheme in connection with Valeant's attempted $55 billion takeover of Allergan Inc. urged a California federal court on Monday to strike three pages about the U.S. Securities and Exchange Commission from a recent Pershing brief as "irrelevant, immaterial, impertinent and inadmissible."
July 11, 2017
Valeant Pharmaceuticals and hedge fund Pershing Square Capital Management LP sought quick wins Monday in an investor suit accusing the firms of insider trading, telling a California federal court that the firms' collaboration on Valeant's attempted $55 billion takeover of Allergan was "legitimate group activity."
July 05, 2017
Investors behind a class action accusing hedge fund Pershing Square and Valeant Pharmaceuticals of an insider trading scheme in connection with Valeant's attempted $55 billion takeover of Allergan Inc. have told a California federal court that the two firms are wrongly trying to use the U.S. Securities and Exchange Commission as a shield.
May 16, 2017
Valeant Pharmaceuticals and Pershing Square Capital Management LP have objected to the notification procedures proposed in a newly certified class action over insider trading claims related to an attempted $55 billion takeover of Allergan Inc., telling a California federal court on Monday that the investors behind the suit aren't giving derivative traders an adequate chance to participate.
March 15, 2017
A California federal judge on Wednesday granted class certification in a stock-drop suit against Valeant Pharmaceuticals and William Ackman's Pershing Square Capital Management LP over an attempted $55 billion takeover of Allergan Inc., saying Allergan investors who sold their stock have alleged common losses that bind them together.
February 13, 2017
Valeant Pharmaceuticals International Inc. and William Ackman's hedge fund Pershing Square Capital Management have agreed to split litigation costs in a putative class action over an alleged insider trading scheme in 2014's Allergan takeover bid, according to a filing made Monday with the U.S. Securities and Exchange Commission.
December 21, 2016
A California federal special master has denied an email subpoena bid by Pershing Square Capital Management LP against Bernstein Litowitz Berger & Grossmann LLP, which represents investors alleging that Valeant Pharmaceuticals International Inc. illegally tipped Pershing Square to a proposed merger.